LQDA
Liquidia Corporation
There isn't enough reported data to score LQDA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LQDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Strong | |
| Strong |
LQDA's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LQDA PE Valuation
LQDA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LQDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for LQDA, but weaker profitability. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over LQDA on the outlook, with more favorable profitability expectations.
LQDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.15 | — |
| Q3 2026 | -$1.20 | +$0.23 |
| Q2 2026 | $1.40 | +$3.09 |
| Q1 2026 | $0.17 | +$1.74 |
| Q4 2025 | -$0.80 | +$0.86 |
| Q3 2025 | -$1.43 | +$0.21 |
| Q2 2025 | -$1.69 | -$0.11 |
| Q1 2025 | -$1.57 | $0.00 |
| Q4 2024 | -$1.66 | -$0.45 |
LQDA is still losing money, but far less than before: $1.20 per share over the past year, against $2.60 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over LQDA on earnings quality, reporting a profit while its opponent remains loss making.
LQDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $225.3M | +315% |
| Q2 2026 | $171.7M | +1843% |
| Q1 2026 | $132.9M | +4158% |
| Q4 2025 | $92M | +3055% |
| Q3 2025 | $54.3M | +1122% |
| Q2 2025 | $8.8M | +142% |
| Q1 2025 | $3.1M | +5% |
| Q4 2024 | $2.9M | -36% |
LQDA's revenue has grown year over year for seven quarters in a row: $225M last quarter, up 315% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -117% | -120 points |
| Q2 2026 | 50% | +474 points |
| Q1 2026 | 46% | +1182 points |
| Q4 2025 | 22% | +1259 points |
| Q3 2025 | 3.3% | +660 points |
| Q2 2025 | -424% | +319 points |
| Q1 2025 | -1135% | -166 points |
| Q4 2024 | -1238% | -654 points |
LQDA's operating margin was −117% last quarter, down 120 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over LQDA on profitability, with a higher operating margin.
LQDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $129.8M | +$140.5M |
| Q2 2026 | $69M | +$109.5M |
| Q1 2026 | $50.2M | +$81.2M |
| Q4 2025 | $42.2M | +$64.3M |
| Q3 2025 | -$10.7M | +$16.1M |
| Q2 2025 | -$40.5M | -$16.6M |
| Q1 2025 | -$31M | -$5.5M |
| Q4 2024 | -$22.1M | -$5.9M |
LQDA's free cash flow has turned positive after six years mostly in the red: $291M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LQDA on cash flow, with more consistent year-over-year improvement.
LQDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -12% | -11.9M shares |
| 1 year | +3.7% | +3.2M shares |
| 3 years | +38% | +24.7M shares |
| 5 years | +72% | +37.4M shares |
| Available history | +340% | +69.2M shares |
LQDA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LQDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
LQDA has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over LQDA on leverage, with a lower net debt burden relative to earnings.
LQDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.2 | Neutral |
| Stochastic | 37.7 | Neutral |
LQDA's weekly RSI is 52 (neutral) and its Stochastic is 38 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LQDA PE vs Healthcare Sector
| Metric | LQDA | Sector median | Relative |
|---|---|---|---|
| PE | 32x | 26x | 23% above |
| PE % | 16 | 29 | 13 pts below |
LQDA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over LQDA on valuation relative to its sector.
LQDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.6 | 33% above |
| 20 week MA | $63.0 | 7.7% below |
| 50 week MA | $51.4 | 13% above |
| 100 week MA | $34.9 | 67% above |
| 200 week MA | $22.3 | 160% above |
LQDA's trend is mixed: it's above four of its five weekly moving averages, and 160% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LQDA on trend strength, trading above more of its moving averages.
LQDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.94 | $2.82 | -43% |
| 2021 | $2.82 | $4.67 | +66% |
| 2022 | $4.67 | $6.17 | +32% |
| 2023 | $6.17 | $12.0 | +95% |
| 2024 | $12.0 | $11.6 | -3.8% |
| 2025 | $11.6 | $34.4 | +197% |
| 2026 YTD | $34.4 | $58.1 | +69% |
LQDA's yearly returns have swung widely, from +197% in 2025 to −43% in 2020. It's up 69% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LQDA on returns for 2026, with the stronger performance.